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Oral Fixed Drug Eruption Secondary to Isoniazid
Tanya Ermolovich, DO and Tatyana Groysman, DO, Lehigh Valley Health Network, Allentown, Pennsylvania
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Figure 1: Right upper
mucosal lip, 3cm
thickened, beefy red
plaque with superficial fissures. Patient
was on INH at the
time.

Figure 2: Right upper
mucosal lip, well
healed lesion 3 weeks
after IHN was dis
continued.
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Figure 3: H&E (4x) Shave
biopsy from the lesion in
figure 3 showing acutely
inflamed granulation
tissue and overlying layer
of fibrino-neutrophilic
debris.
Figure 4: H&E (10x)
Higher power of fibroneutrophilic debris and
granulation tissue.

Patient: P.S. is a 60 year-old Caucasian female.
History of Present Illness: The patient presented to our

dermatology practice complaining of 2 months duration of painful sores
inside her mouth. Two weeks prior to the eruption she was started on
isoniazid (INH) and vitamin B-6 for treatment of a positive PPD found on
routine screening. The patient was seen by her PCP before presenting to
our office and was put on valacyclovir for a presumed HSV outbreak,
without improvement. Viral and bacterial cultures were negative; however
the patient was on valacyclovir at the time. She offered no complaints
other than the burning and occasional bleeding inside the mouth.
Medical History/Surgical History: HTN, osteo
porosis, psoriasis, psoriatic arthritis, seasonal allergies, tuberculosis,
joint replacement, appendectomy, hysterectomy (uterine tumor)
Medications: Celebrex, hydroxychloroquine, methotrexate,
teriparatide, simvastatin, folic acid, vitamin D, rifampin
Previous Treatments: Valacyclovir, prednisone taper,
desoximetasone topical gel
Physical Examination: The right upper mucosal lip has a
3 cm thickened, beefy red plaque with superficial fissures. Her right
lower mucosal lip has a healing erosion. On the left side of the dorsal
tongue a 6 mm x 3 mm ulceration is noted. No lesions were seen on the
genital mucosa and no other cutaneous findings were present.
Studies: Viral and bacterial cultures: negative
Biopsy: CBLPath (D10NY1-0379575, 11/5/10) Lower lip: “Mostly
acutely inflamed granulation tissue and overlying layer of fibrino-
neutrophilic debris. The findings appear nonspecific.”
Direct Immunofluorescence: Negative
Reason for Presentation: Interest
Discussion: Fixed drug eruption (FDE) is a distinctive variant of a
drug eruption with characteristic recurrence at the same site of skin or
mucous membranes and spontaneous resolution upon discontinuation of
the causative agent. The initial eruption is often solitary and frequently
located on the lip or genitalia. Involvement of the mucosa only without
any skin involvement, as in the case of our patient, is extremely rare.
Clinically, the lesions on mucosal surfaces may be edematous plaques or
pigmented patches with an erythematous halo. The lesions may often
become vesicular or bullous and rupture leaving erosions. With the initial
attack, the period required for sensitization is highly
variable ranging from a few weeks to several years.
Subsequent re-exposure to the medication results in

r eactivation of the old lesion and occasionally d evelopment of new ones,
within approximately 2 hours.
The exact mechanism for the development of the FDE lesions is
unknown. It is believed to be triggered by activation of intraepidermal
CD8+ T cells and additional recruitment of CD4+ and CD8+ T cells from
the circulation causing extensive tissue damage observed in fully
evolved lesions. It is hypothesized that intraepidermal CD8+ T cells are
strategically seeded to the epidermis upon contact with infection or
trauma as they are similar in phenotype and function to virus-specific
effector–memory CD8+ T cells.
The major categories of causative agents of FDE include antibiotics,
antiepileptics, nonsteroidal anti-inflammatory agents (NSAIDs), and phenothiazines. The drugs frequently associated with mucosal FDE are
sulfonamides (especially TMP-SMX), NSAIDs (in particular, phenazone
derivatives) and tetracyclines. Recent literature describes case reports of
oral FDE secondary to fluconazole and gabapentin.
Different adverse dermatological reactions have been reported with INH.
Many of these are hypersensitivity reactions such as urticaria, angioedema
and morbiliform eruptions. To the best of our knowledge, this is a unique
case of oral FDE caused by INH.
The main goal of treatment is to identify the causative agent and avoid
it. Rechallenging the patient, either by patch testing the lesional skin or
oral provocation (most reliable test) are the only known tests to possibly
identify the suspected agent. Our patient refused a rechallenge because
of great discomfort associated with the eruption. However, resolution of
her oral lesions within 3 weeks and no recurrence at 12 weeks follow-up
since discontinuation of INH, strongly supports it being the causative
agent.
FDE lesions can be treated for symptomatic relief. In this case, the
patient did well with a potent topical corticosteroid and a short, low-dose
prednisone taper.
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